Liede Alexander, Hernandez Rohini K, Tang En-Tzu, Li Chuang, Bennett Brian, Wong Steven S, Jandial Danielle
Center for Observational Research, Amgen, 1120 Veterans Boulevard, ASF3, Thousand Oaks and South San Francisco, CA, USA.
Oncology, R&D, Amgen China, RM. 1501∼1506, 15F of Platinum Tower, No. 233 Taicang Road, HuangPu District, Shanghai 200020 PR China.
J Bone Oncol. 2018 Jul 26;12:96-100. doi: 10.1016/j.jbo.2018.07.003. eCollection 2018 Sep.
Quantifying the incidence of giant cell tumor (GCT) of bone is challenging because it is a rare, histologically benign bone tumor for which population-level statistics are unavailable in most countries. We estimated the 2017 incidence of GCT in China using a direct (registry-based) approach with available population-based data.
The most recent age- and sex-specific incidence rates of GCT recorded in the Bone Tumor Registry in Japan (2015) were applied to 2017 age- and sex-matched populations projected by the United Nations for China in order to estimate 2017 incidence. An adjustment factor calculated using registry data suggesting that GCT may represent a greater proportion of bone tumors in China than in Japan (Guo, 1999) was applied to provide secondary estimates.
Annual GCT incidence was estimated to be 1.49 per million population or 2094 new cases in China for 2017. A comparison of this estimated incidence with Japan (1.25 per million) and the United States (1.38 per million) indicates that the incidence is somewhat higher in China using identical methods. Secondary estimates suggest that GCT incidence in China may be as high as 2.57 per million or 3625 new cases in 2017. The corresponding 3-year limited-duration prevalence of GCT in China using a registry-based approach and general age-specific mortality is 6276 (secondary estimate: 10,876).
Leveraging unique population-based registry data, we estimated that GCT is a rare disease in the Chinese population with an incidence ranging between 1.49 and 2.57 cases per million persons per year. Possible differences in diagnostic classification of GCT, urban-rural demographics, and the younger demographic distribution of the Chinese population may underlie observations that GCT, a condition that primarily affects young individuals (20-40 years of age), accounts for a higher proportion of skeletal tumors in China than in other regions.
骨巨细胞瘤(GCT)的发病率量化颇具挑战,因为它是一种罕见的组织学上为良性的骨肿瘤,在大多数国家缺乏基于人群层面的统计数据。我们采用直接(基于登记处)的方法并利用现有的基于人群的数据来估算2017年中国骨巨细胞瘤的发病率。
将日本骨肿瘤登记处(2015年)记录的骨巨细胞瘤最新年龄和性别特异性发病率应用于联合国预测的2017年中国年龄和性别匹配的人群,以估算2017年的发病率。使用登记处数据计算得出的调整因子(表明骨巨细胞瘤在中国可能占骨肿瘤的比例高于日本(郭,1999年))用于提供二次估算。
估计2017年中国骨巨细胞瘤的年发病率为每百万人口1.49例,即2094例新发病例。将这一估计发病率与日本(每百万人口1.25例)和美国(每百万人口1.38例)进行比较表明,采用相同方法时中国的发病率略高。二次估算表明,2017年中国骨巨细胞瘤的发病率可能高达每百万人口2.57例或3625例新发病例。使用基于登记处的方法和一般年龄特异性死亡率计算得出的中国骨巨细胞瘤相应的3年有限期患病率为6276例(二次估算:10876例)。
利用独特的基于人群的登记处数据,我们估计骨巨细胞瘤在中国人群中是一种罕见疾病,发病率为每年每百万人口1.49至2.57例。骨巨细胞瘤诊断分类、城乡人口统计学以及中国人口较年轻的年龄分布可能是导致骨巨细胞瘤(一种主要影响年轻人(20 - 40岁)的疾病)在中国骨骼肿瘤中所占比例高于其他地区这一观察结果的潜在原因。